Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 03/20/17
End: 11/05/20
Due: 11/05/21
Phase: N/A
Priority: Normal
Start: 06/22/18
End: 07/31/20
Due: 07/31/21
Phase: N/A
Priority: Normal
Start: 10/09/19
End: 12/31/21
Due: 12/31/22
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Study of AMV564 in Patients With AML | NCT03144245 | Amphivena Therapeutics, Inc. | user2@example.com | None | 2017-03-20 | 2020-11-05 | 2021-11-05 | - | - | 2025-07-14 |
| A Phase 1 Study of AMV564 in Patients With Intermediate or High-Risk Myelodysplastic Syndromes | NCT03516591 | Amphivena Therapeutics, Inc. | user2@example.com | None | 2018-06-22 | 2020-07-31 | 2021-07-31 | - | - | 2025-07-14 |
| Study of AMV564 in Subjects With Advanced Solid Tumors | NCT04128423 | Amphivena Therapeutics, Inc. | user2@example.com | None | 2019-10-09 | 2021-12-31 | 2022-12-31 | - | - | 2025-07-14 |